We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Worm Study: Modifier Genes in Sudden Cardiac Death

This study is currently recruiting participants.
Verified May 2015 by Maastricht University Medical Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT02014961
First Posted: December 19, 2013
Last Update Posted: May 14, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Netherlands Heart Foundation
Information provided by (Responsible Party):
Maastricht University Medical Center
  Purpose
Quest for modifier genes associated with ventricular arrhythmias in presence of a cardiac sodium channel gene (SCN5A-delPhe1617) mutation.

Condition Intervention
Brugada Syndrome Long QT Syndrome 3 Procedure: Dermal biopsy Behavioral: Gastro-intestinal questionnaire Genetic: Whole-exome sequencing

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Diagnostic
Official Title: Worm Study: Identification of Modifier Genes in a Unique Founder Population With Sudden Cardiac Death

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Difference in genetic profile (e.g. modifier genes) between mutation carriers expressing different phenotypes and non-mutation carriers. [ Time Frame: two years ]

Estimated Enrollment: 223
Study Start Date: April 2015
Estimated Study Completion Date: April 2025
Estimated Primary Completion Date: April 2025 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Mutation Carriers
Whole-exome sequencing (WES) Dermal biopsy Gastro-intestinal questionnaire
Procedure: Dermal biopsy
Skin biopsy
Behavioral: Gastro-intestinal questionnaire
Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
Genetic: Whole-exome sequencing
Whole-exome sequencing (WES)
Placebo Comparator: Non-Mutation Carriers
Whole-exome sequencing (WES) Gastro-intestinal questionnaire
Behavioral: Gastro-intestinal questionnaire
Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
Genetic: Whole-exome sequencing
Whole-exome sequencing (WES)
Spouse
Whole-exome sequencing (WES) 12-Lead ECG
Genetic: Whole-exome sequencing
Whole-exome sequencing (WES)

Detailed Description:
In a large Dutch SCN5A founder population with malignant ventricular arrhythmias, the investigators aim to identify genetic modifiers by means of whole-exome sequencing and to establish a comprehensive genotype-phenotype correlation, focussing on clinical and cellular electrophysiological characteristics and neurocardiac modulation.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria (mutation carrier group):

  • Age ≥ 18 years.
  • Heterozygous or homozygous carriership of SCN5A-delPhe1617.
  • Confirmed kinship to the founder population by haplotype analysis using predefined microsatellite markers.
  • Written informed consent.

Inclusion Criteria (non-mutation carrier group):

  • Age ≥ 18 years.
  • Non SCN5A-delPhe1617 genotype.
  • Confirmed kinship to the Founder Group by haplotype analysis using predefined microsatellite marker.
  • Written informed consent.

Inclusion criteria Spouse Group

  • Age ≥ 18 years.
  • Biological parent of SCN5A-delPhe1617 positive subject participating to the Worm Study, and not belonging to study group 1 or 2.
  • Written informed consent.

Exclusion Criteria:

  • Age ≥ 18 years.
  • Biological parent of SCN5A-delPhe1617 positive subject participating to the Worm Study, and not belonging to study group 1 or 2.
  • Written informed consent.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02014961


Contacts
Contact: Rachel ter Bekke, M.D. +31433877098 rachel.ter.bekke@mumc.nl
Contact: Paul Volders, M.D., Ph.D. +31433877097 p.volders@maastrichtuniversity.nl

Locations
Netherlands
Maastricht University Medical Center Recruiting
Maastricht, Limburg, Netherlands, 6202 AZ
Contact: ter Bekke    +31433877098    rachel.ter.bekke@mumc.nl   
Sponsors and Collaborators
Maastricht University Medical Center
Netherlands Heart Foundation
Investigators
Study Director: Paul Volders, M.D., Ph.D. Maastricht University Medical Centre
  More Information

Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT02014961     History of Changes
Other Study ID Numbers: METC 142060
First Submitted: December 9, 2013
First Posted: December 19, 2013
Last Update Posted: May 14, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Long QT Syndrome
Syndrome
Death
Death, Sudden, Cardiac
Brugada Syndrome
Disease
Pathologic Processes
Heart Arrest
Heart Diseases
Cardiovascular Diseases
Death, Sudden
Arrhythmias, Cardiac
Heart Defects, Congenital
Cardiovascular Abnormalities
Congenital Abnormalities
Genetic Diseases, Inborn